Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25776297 | 0.90 | — | — | |
| SCHEMBL1106480 | 0.82 | CHRM3 (0.41) | CHRM3CASP3CHRNB4CHRNA3 | |
| SCHEMBL57317 | 0.82 | CHRM3 (0.41) | CHRM3CASP3CHRNB4CHRNA3 | |
| SCHEMBL278415 | 0.82 | CHRM3 (0.41) | CHRM3CASP3CHRNB4CHRNA3 | |
| SCHEMBL13910186 | 0.80 | CHRM3 (0.34) | CHRM3 | |
| SCHEMBL18596039 | 0.80 | CHRM3 (0.34) | CHRM3 | |
| SCHEMBL26724276 | 0.79 | TSHR (0.34) | CHRM3SLC2A1 | |
| SCHEMBL24599464 | 0.78 | CHRM3 (0.33) | CHRM3 | |
| SCHEMBL3977447 | 0.78 | CHRM3 (0.33) | CHRM3 | |
| SCHEMBL29174460 | 0.78 | CHRM3 (0.33) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | CHRM3 3721/4885CASP1 2/4885CASP3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.